Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsFRA:S0N0 -2.05%19 Return-on-Tangible-Asset is -37.60% as of Apr. 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, enGene Therapeutics ranks worse than 57.78% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. enGene Therapeutics's annualizedNet Income for the quarter that ended in Apr. 2026 was €-103.38 Mil. enGene Therapeutics's average total tangible assets for the quarter that ended in Apr. 2026 was €274.91 Mil. Therefore, enGene Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2026 was -37.60%.
The historical rank and industry rank for enGene Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
FRA:S0N0'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -180.24 Med: -125.65 Max: -27.7
Current: -46.02
During the past 6 years, enGene Therapeutics's highest Return-on-Tangible-Asset was -27.70%. The lowest was -180.24%. And the median was -125.65%.
FRA:S0N0's Return-on-Tangible-Asset is ranked worse than 57.78% of 1414
companies
in the Biotechnology industry
Industry Median: -36.16
vs FRA:S0N0: -46.02
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
enGene Therapeutics Return-on-Tangible-Asset Related Terms
enGene Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S0N0 vs VTVT, GUTS, VXRT: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, enGene Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
What does a Return-on-Tangible-Asset of -37.60% mean?
enGene Therapeutics (FRA:S0N0) has a Return-on-Tangible-Asset of -37.60% as of Apr. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #817 out of 1414 companies in the Biotechnology industry, placing it in the top 57.8%.
Is enGene Therapeutics' Return-on-Tangible-Asset too high?
enGene Therapeutics' current Return-on-Tangible-Asset is -37.60%. Based on the distribution chart, enGene Therapeutics ranks #817 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Return-on-Tangible-Asset compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #817 out of 1414 companies for Return-on-Tangible-Asset. This places enGene Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Return-on-Tangible-Asset is -37.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Return-on-Tangible-Asset of -37.60%. The current Return-on-Tangible-Asset is -37.60%. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Return-on-Tangible-Asset is -37.60% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score
Get the complete analysis for FRA:S0N0
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S0N0 has been successfully added to your 
